Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001831942-25-000031
Filing Date
2025-11-14
Accepted
2025-11-14 17:08:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7198
2 exhibit1jointfilingagreement.htm EX-1 2488
  Complete submission text file 0001831942-25-000031.txt   11704
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 251488076
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022 212-256-8600
Commodore Capital LP (Filed by) CIK: 0001831942 (see all company filings)

EIN.: 832659606 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A